{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:03:54Z","timestamp":1762866234339,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S3","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1186\/1752-0509-7-s3-s3","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T15:03:21Z","timestamp":1381935801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models"],"prefix":"10.1186","volume":"7","author":[{"given":"Kenta","family":"Yoshida","sequence":"first","affiliation":[]},{"given":"Kazuya","family":"Maeda","sequence":"additional","affiliation":[]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[]},{"given":"Akihiko","family":"Konagaya","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,10,16]]},"reference":[{"key":"1160_CR1","first-page":"17","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"I Buxton","year":"2010","unstructured":"Buxton I, Benet L: Chapter 2. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Edited by: Brunton L, Chabner B, Knollmann B. 2010, New York: McGraw-Hill, 17-39. 12th","edition":"12th"},{"key":"1160_CR2","first-page":"145","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"M Relling","year":"2010","unstructured":"Relling M, Giacomini K: Chapter 7. Pharmacogenetics. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Edited by: Brunton L, Chabner B, Knollmann B. 2010, New York: McGraw-Hill, 145-168. 12th","edition":"12th"},{"issue":"12","key":"1160_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"R Verbeeck","year":"2008","unstructured":"Verbeeck R: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008, 64 (12): 1147-1161. 10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1160_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"R Verbeeck","year":"2009","unstructured":"Verbeeck R, Musuamba F: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009, 65 (8): 757-773. 10.1007\/s00228-009-0678-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"1160_CR5","first-page":"263","volume-title":"Molecular Interactions","author":"A Konagaya","year":"2012","unstructured":"Konagaya A: Towards an In Silico Approach to Personalized Pharmacokinetics. Molecular Interactions. 2012, Edited by Meghea A. Rijeka, Croatia: Intech, 263-282."},{"key":"1160_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland M, Peck C, Tucker G: Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011, 51: 45-73. 10.1146\/annurev-pharmtox-010510-100540.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1160_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC: Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011, 89 (2): 259-267. 10.1038\/clpt.2010.298.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1160_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/138920010794328931","volume":"11","author":"J Fan","year":"2010","unstructured":"Fan J, Chen S, Chow EC, Pang KS: PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab. 2010, 11 (9): 743-761. 10.2174\/138920010794328931.","journal-title":"Curr Drug Metab"},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev-pharmtox-011112-140309","volume":"53","author":"K Yoshida","year":"2013","unstructured":"Yoshida K, Maeda K, Sugiyama Y: Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol. 2013, 53: 581-612. 10.1146\/annurev-pharmtox-011112-140309.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"1160_CR10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","volume":"46","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003, 46 (3): 347-351.","journal-title":"Diabetologia"},{"key":"1160_CR11","unstructured":"Draft Guidance\/Guidance for Industry. Drug Interaction Studies--Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. [http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf]"},{"key":"1160_CR12","volume-title":"NII Technical Reports","author":"Y Aoki","year":"2011","unstructured":"Aoki Y, Hayami K, Sterc HD, Konagaya A: Cluster Newton Method for Sampling Multiple. Solutions of an Underdetermined Inverse Problem: Parameter Identification for Pharmacokinetics. NII Technical Reports. 2011"},{"issue":"Suppl 6","key":"1160_CR13","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1471-2105-9-S6-S11","volume":"9","author":"T Arikuma","year":"2008","unstructured":"Arikuma T, Yoshikawa S, Azuma R, Watanabe K, Matsumura K, Konagaya A: Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation. BMC bioinformatics. 2008, 9 (Suppl 6): S11-10.1186\/1471-2105-9-S6-S11.","journal-title":"BMC bioinformatics"},{"issue":"4","key":"1160_CR14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab lism and Disposition: The Biological Fate of Chemicals. 2000, 28 (4): 423-433.","journal-title":"Drug Metab lism and Disposition: The Biological Fate of Chemicals"},{"issue":"2","key":"1160_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","volume":"20","author":"NF Smith","year":"2006","unstructured":"Smith NF, Figg WD, Sparreboom A: Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006, 20 (2): 163-175. 10.1016\/j.tiv.2005.06.045.","journal-title":"Toxicol In Vitro"},{"issue":"16","key":"1160_CR16","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009, 27 (16): 2604-2614. 10.1200\/JCO.2008.20.6300.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1160_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1124\/dmd.104.001909","volume":"33","author":"T Nozawa","year":"2005","unstructured":"Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug metabolism and disposition: the biological fate of chemicals. 2005, 33 (3): 434-439.","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"16","key":"1160_CR18","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T: Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996, 56 (16): 3752-3757.","journal-title":"Cancer Res"},{"issue":"3","key":"1160_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00280-008-0769-8","volume":"63","author":"IR Younis","year":"2009","unstructured":"Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP: Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol. 2009, 63 (3): 517-524. 10.1007\/s00280-008-0769-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1160_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00423-005-0564-5","volume":"390","author":"T Yamada","year":"2005","unstructured":"Yamada T, Arai T, Nagino M, Oda K, Shoda J, Suzuki H, Sugiyama Y, Nimura Y: Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer. Langenbecks Arch Surg. 2005, 390 (5): 421-429. 10.1007\/s00423-005-0564-5.","journal-title":"Langenbecks Arch Surg"},{"issue":"4","key":"1160_CR21","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/j.gastro.2003.12.046","volume":"126","author":"CG Dietrich","year":"2004","unstructured":"Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S, Gartung C: Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology. 2004, 126 (4): 1044-1053. 10.1053\/j.gastro.2003.12.046.","journal-title":"Gastroenterology"},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1137\/S1064827594276424","volume":"18","author":"L Shampine","year":"1997","unstructured":"Shampine L, Reichelt M: The matlab ode suite. SIAM journal on scientific computing. 1997, 18: 1-10.1137\/S1064827594276424.","journal-title":"SIAM journal on scientific computing"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-0509-7-S3-S3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T17:17:40Z","timestamp":1746033460000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/1752-0509-7-S3-S3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":22,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1186\/1752-0509-7-s3-s3","relation":{},"ISSN":["1752-0509"],"issn-type":[{"type":"electronic","value":"1752-0509"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"16 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S3"}}